PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-5.03
Negative P/E while Healthcare median is -1.87. Seth Klarman would scrutinize path to profitability versus peers.
4088.78
P/S exceeding 1.5x Healthcare median of 8.92. Jim Chanos would check for potential multiple compression risks.
2.58
P/B 1.25-1.5x Healthcare median of 2.06. Guy Spier would scrutinize if premium reflects better asset utilization.
-31.79
Negative FCF while Healthcare median P/FCF is -8.10. Seth Klarman would investigate cash flow improvement potential.
-32.20
Negative operating cash flow while Healthcare median P/OCF is -7.08. Seth Klarman would investigate operational improvement potential.
2.58
Fair value ratio 1.25-1.5x Healthcare median of 2.06. Guy Spier would scrutinize if premium reflects durable advantages.
-4.97%
Negative earnings while Healthcare median yield is -1.95%. Seth Klarman would investigate path to profitability.
-3.15%
Negative FCF while Healthcare median yield is -1.35%. Seth Klarman would investigate cash flow improvement potential.